Tratamiento antirretroviral de la infección por el VIH - libdoc.who.int
Tratamiento antirretroviral de la infección por el VIH - libdoc.who.int
Tratamiento antirretroviral de la infección por el VIH - libdoc.who.int
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
188. Llibre JM, Santos JR, Puig T, Molto J, Ruiz L, Pare<strong>de</strong>s R, et al. Prevalence of etravirineassociated<br />
mutations in clinical samples with resistance to nevirapine and efavirenz. J<br />
Antimicrob Chemother 2008;62(5):909-13.<br />
189. Poveda E, Anta L, B<strong>la</strong>nco JL, Perez-Elias MJ, Garcia F, Leal M, et al. Etravirine resistance<br />
associated mutations in HIV-infected patients failing efavirenz or nevirapine in the Spanish<br />
antiretroviral resistance database. AIDS 2010;;24(3 ):469–71..<br />
190. Geretti AM. Shifting paradigms: the resistance profile of etravirine. J Antimicrob Chemother<br />
2008;62(4):643-7.<br />
191. Sungkanuparph S, Manosuthi W, Kiertiburanakul S, Piyavong B, Chantratita W. Evaluating<br />
he role of etravirine in the second-line antiretroviral therapy after failing an initial nonnucleosi<strong>de</strong><br />
reverse transcriptase inhibitor-based regimen in a resource-limited setting.<br />
Curr HIV Res 2008;6(5):474-6.<br />
192. Tibotec Therapeutics icwtUSFaDA. Dear Healthcare Professional letter. 2009: Avai<strong>la</strong>ble from:<br />
http://www.tibotectherapeutics.com/tibotectherapeutics/documents/INTELENCE_DHCP.pdf.<br />
193. WHO. Essential prevention and care <strong>int</strong>erventions for adults and adolescents living with<br />
HIV in resource-limited settings. 2008. Avai<strong>la</strong>ble from: http://www.<strong>who</strong>.<strong>int</strong>/entity/hiv/pub/<br />
prev_care/OMS_EPP_AFF_en.pdf.<br />
194. DiClemente RJ, Wingood GM, D<strong>el</strong> Rio C, Crosby RA. Prevention <strong>int</strong>erventions for HIV<br />
positive individuals. Sex Transm Infect 2002;78(6):393-5.<br />
195. King-Spooner S. HIV prevention and the positive popu<strong>la</strong>tion. Int J STD AIDS 1999;10(3):141-<br />
50.<br />
196. WHO. Priority Interventions HIV/AIDS prevention, treatment and care in the health sector.<br />
2009.<br />
197. Kalichman SC, Cain D, Knetch J, Hill J. Patterns of sexual risk behavior change among<br />
sexually transmitted infection clinic patients. Arch Sex Behav 2005;34(3):307-19.<br />
198. Margolin A, Avants SK, Warburton LA, Hawkins KA, Shi J. A randomized clinical trial of a<br />
manual-gui<strong>de</strong>d risk reduction <strong>int</strong>ervention for HIV-positive injection drug users. Health<br />
Psychol 2003;22(2):223-8.<br />
199. Sterk CE, Theall KP, Elifson KW, Kid<strong>de</strong>r D. HIV risk reduction among African-American<br />
women <strong>who</strong> inject drugs: a randomized controlled trial. AIDS Behav 2003;7(1):73-86.<br />
200. WHO. WHO 3’Is for HIV/TB – Intensified case finding (ICF), isoniazid preventive therapy<br />
(IPT) and TB infection control (IC) for people living with HIV. Re<strong>por</strong>t of a Jo<strong>int</strong> World Health<br />
Organization, HIV/AIDS and TB Department meeting. Geneva: 2008.<br />
201. Walker AS, Ford D, Gilks CF, Mun<strong>de</strong>ri P, Ssali F, Reid A, et al. Daily co-trimoxazole<br />
prophy<strong>la</strong>xis in sever<strong>el</strong>y immunosuppressed HIV-infected adults in Africa started on<br />
combination antiretroviral therapy: an observational analysis of the DART cohort. Lancet<br />
2010;375(9722):1278-86.<br />
147
Change language